ConsortiaTX, Inc. is a seed stage, pre-clinical bio-therapeutics company that emerged from research laboratories at Brigham & Women’s Hospital and Children’s Hospital in Boston. The company’s intellectual property around food allergies and the human gut microbiome is based on the work of Lynn Bry, M.D., Ph.D., Georg Gerber, M.D., Ph.D. (both at BWH), and Talal Chatilla, Ph.D. (at CHB) and others.
Consortia Therapeutics develops microbial therapies to prevent and treat human disease and allergies.
Our work is based upon evidence-based studies from the Massachusetts Host Microbiome Center and the research of its scientific founders.
Why Address Food Allergies?
- There are up to 170 foods reported to trigger reactions. Of these, peanuts, milk, eggs, tree nuts, wheat, soy, fish and shellfish are among the most common.
- Symptoms can range from mild (itchiness) to severe (difficulty breathing) and may lead to anaphylactic shock, leading to death, with server exposure and no treatment.
- Upwards of 15% of all Americans (~50 million) are allergic to one or more foods and the prevalence of food allergies in children has risen rapidly in the past 15 years to more than 6 million children under the age of 18. The number of children with more than one allergy has more than tripled as well.
- The number one approach to dealing with allergies is to avoid foods that trigger the response and, if unsuccessful, carry an EpipenTM to quickly stop the reaction.
- Prevention & treatment cost the economy more than $25 billion annually.
- Health Care providers estimate that about $7 billion is spent each year on visits to allergists, and the available minimally effective treatments, de-sensitization and other oral immuno-therapies.
- source: www.foodallergy.org/facts-and-stats